Xellar Biosystems

About Xellar Biosystems

Xellar Biosystems utilizes a pharma-scale organ-on-chip platform powered by image-based AI to replicate human biological systems for drug testing. This approach addresses the limitations of traditional drug discovery methods by providing more accurate preclinical data, thereby accelerating the development of new therapeutics.

```xml <problem> Traditional drug discovery methods rely on simplified models that fail to capture the complexity of human biology, leading to inaccurate preclinical data and hindering the development of effective therapeutics. These limitations result in increased costs and prolonged timelines for bringing new drugs to market. </problem> <solution> Xellar Biosystems offers a pharma-scale organ-on-chip platform that replicates human biological systems for more accurate drug testing. By combining large-scale wet-lab experiments with image-based AI and machine learning, the platform provides a more holistic and interconnected representation of human biology. This approach enables researchers to generate preclinical data that better reflects human responses to drugs, accelerating the identification and development of promising therapeutic candidates. The platform integrates engineering, pre-clinical development, imaging, and computational modules to provide a comprehensive solution for drug discovery. </solution> <features> - Micro-organ matrix engineering to create realistic in-vitro models - Preclinical development platform for compound testing and validation - High-content imaging platform for detailed data acquisition - AI/ML system for data analysis and predictive modeling - Scalable platform suitable for pharma-scale drug discovery - Integration of wet-lab experiments with AI-driven computation </features> <target_audience> The primary customers are pharmaceutical companies and research institutions seeking to improve the accuracy and efficiency of their drug discovery process. </target_audience> ```

What does Xellar Biosystems do?

Xellar Biosystems utilizes a pharma-scale organ-on-chip platform powered by image-based AI to replicate human biological systems for drug testing. This approach addresses the limitations of traditional drug discovery methods by providing more accurate preclinical data, thereby accelerating the development of new therapeutics.

Where is Xellar Biosystems located?

Xellar Biosystems is based in Newton, United States.

When was Xellar Biosystems founded?

Xellar Biosystems was founded in 2022.

How much funding has Xellar Biosystems raised?

Xellar Biosystems has raised 23780000.

Location
Newton, United States
Founded
2022
Funding
23780000
Employees
18 employees
Major Investors
TriApex
Looking for specific startups?
Try our free semantic startup search

Xellar Biosystems

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Xellar Biosystems utilizes a pharma-scale organ-on-chip platform powered by image-based AI to replicate human biological systems for drug testing. This approach addresses the limitations of traditional drug discovery methods by providing more accurate preclinical data, thereby accelerating the development of new therapeutics.

xellarbio.com2K+
cb
Crunchbase
Founded 2022Newton, United States

Funding

$

Estimated Funding

$23.8M+

Major Investors

TriApex

Team (15+)

XuHai Huang

Senior Engineer

Company Description

Problem

Traditional drug discovery methods rely on simplified models that fail to capture the complexity of human biology, leading to inaccurate preclinical data and hindering the development of effective therapeutics. These limitations result in increased costs and prolonged timelines for bringing new drugs to market.

Solution

Xellar Biosystems offers a pharma-scale organ-on-chip platform that replicates human biological systems for more accurate drug testing. By combining large-scale wet-lab experiments with image-based AI and machine learning, the platform provides a more holistic and interconnected representation of human biology. This approach enables researchers to generate preclinical data that better reflects human responses to drugs, accelerating the identification and development of promising therapeutic candidates. The platform integrates engineering, pre-clinical development, imaging, and computational modules to provide a comprehensive solution for drug discovery.

Features

Micro-organ matrix engineering to create realistic in-vitro models

Preclinical development platform for compound testing and validation

High-content imaging platform for detailed data acquisition

AI/ML system for data analysis and predictive modeling

Scalable platform suitable for pharma-scale drug discovery

Integration of wet-lab experiments with AI-driven computation

Target Audience

The primary customers are pharmaceutical companies and research institutions seeking to improve the accuracy and efficiency of their drug discovery process.

Xellar Biosystems - Funding: $20M+ | StartupSeeker